Altimmune's Innovative Approach to Liver Disease at EASL 2025
Overview of Altimmune's Presentation at EASL 2025
Altimmune, Inc. (Nasdaq: ALT), a dedicated biopharmaceutical company, is set to present at the prestigious EASL International Liver Congress™ 2025, showcasing its innovative research on pemvidutide. This cutting-edge clinical research focuses on metabolic dysfunction-associated steatotic liver disease (MASLD) and emphasizes the importance of non-invasive measures in understanding liver health.
Key Aspects of the Presentation
During the congress, Altimmune will discuss analyses of subjects treated with pemvidutide, particularly how it affects the MASH Resolution Index, a key indicator of liver histologic response. This non-invasive measure, developed by Loomba in 2024, provides significant insights into the effectiveness of treatments against MASLD.
Details of the Presentation
The upcoming presentations will delve deep into crucial findings that illustrate the benefits of pemvidutide. The first poster session is titled 'MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment.' Shaheen Tomah, M.D., the Director of Clinical Development at Altimmune, will lead this insightful presentation.
What to Expect During the Session
There will be two key sessions during the congress. The poster tour presentation on Thursday will be part of the MASLD: Therapy section, and offers an exquisite opportunity to engage with the research on May 8, 2025.
Pemvidutide: A Revolutionary Therapeutic Option
Pemvidutide is an investigational peptide-based therapy, acting as a dual receptor agonist that targets GLP-1 and glucagon receptors. This treatment aims to tackle obesity, MASH, alcohol use disorder, and alcohol liver disease. Research suggests that it not only suppresses appetite but also boosts energy expenditure, targeting hepatic fat metabolism effectively.
Clinical Trial Results
In clinical trials, pemvidutide has shown promising results, particularly with a compelling weight loss profile and preservation of lean mass. Patients have also noted considerable reductions in triglycerides and liver fat content. The U.S. FDA has recognized the potential of pemvidutide, granting it Fast Track designation for MASH treatment. As the company moves forward, the recent MOMENTUM Phase 2 obesity trial has concluded successfully, and the ongoing IMPACT Phase 2b trial is generating excitement.
About Altimmune and Its Mission
Altimmune is more than just a biopharmaceutical company; it is a pioneer striving to develop next-generation peptide therapeutics that address significant health challenges. With a portfolio aimed at improving health outcomes for patients suffering from metabolic diseases and liver complications, Altimmune is committed to innovation in the healthcare space.
Stay Informed with Altimmune
The Altimmune team encourages everyone interested in their groundbreaking work to stay updated through their website. The company regularly shares insights and updates regarding their research and upcoming events.
Frequently Asked Questions
What is pemvidutide?
Pemvidutide is a dual receptor agonist aimed at treating various metabolic disorders, including obesity and liver diseases.
Where will Altimmune present their findings?
Altimmune will present at the EASL International Liver Congress™ 2025 in Amsterdam.
Who will present at the congress?
Dr. Shaheen Tomah, the Director of Clinical Development at Altimmune, will lead the presentations.
What is the MASH Resolution Index?
The MASH Resolution Index is a non-invasive tool used to measure histologic responses in liver disease treatments.
How can I learn more about Altimmune?
For more information, visit Altimmune's official website or follow them on their social media platforms.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
